Shattuck Labs (NASDAQ:STTK – Get Free Report) and Gain Therapeutics (NASDAQ:GANX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.
Institutional & Insider Ownership
58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Shattuck Labs and Gain Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shattuck Labs | N/A | -43.57% | -40.90% |
| Gain Therapeutics | N/A | -161.59% | -118.36% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shattuck Labs | 1 | 0 | 10 | 2 | 3.00 |
| Gain Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Shattuck Labs currently has a consensus price target of $13.70, indicating a potential upside of 149.54%. Gain Therapeutics has a consensus price target of $7.67, indicating a potential upside of 443.74%. Given Gain Therapeutics’ higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Shattuck Labs.
Volatility & Risk
Shattuck Labs has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.
Earnings and Valuation
This table compares Shattuck Labs and Gain Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shattuck Labs | $1.00 million | 550.98 | -$48.81 million | ($0.51) | -10.76 |
| Gain Therapeutics | $50,000.00 | 1,230.65 | -$20.16 million | ($0.50) | -2.82 |
Gain Therapeutics has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Shattuck Labs beats Gain Therapeutics on 9 of the 14 factors compared between the two stocks.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
